Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Artificial liver support in acute liver failure.

D J Dowling1, D J Mutimer

  • 1The Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.

European Journal of Gastroenterology & Hepatology
|September 30, 1999
PubMed
Summary

Bioartificial devices aim to support liver function in acute liver failure (ALF). While showing metabolic benefits, these advanced liver support systems have not yet improved patient outcomes or fully resolved safety concerns like zoonotic disease transmission.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: The association of hepatitis C virus infection and post-liver transplant diabetes.

Alimentary pharmacology & therapeutics·2015
Same author

Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection.

International journal of antimicrobial agents·2013
Same author

Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit.

Alimentary pharmacology & therapeutics·2012
Same author

Commentary: SOFA scores and staggered paracetamol overdose prognostication.

Alimentary pharmacology & therapeutics·2012
Same author

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Alimentary pharmacology & therapeutics·2012
Same author

Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy.

Journal of viral hepatitis·2008

Area of Science:

  • Biomedical Engineering
  • Hepatology
  • Regenerative Medicine

Background:

  • The development of bioartificial liver devices is a long-standing goal to treat acute liver failure (ALF).
  • Recent advancements have led to three such devices currently in clinical trials.
  • These devices are designed to mimic the metabolic functions of a healthy liver.

Observation:

  • Current bioartificial devices demonstrate the ability to perform key liver metabolic functions.
  • These functions have shown an impact on the serum biochemistry of patients suffering from ALF.
  • Despite metabolic improvements, a clear benefit to patient survival or recovery in ALF has not been established.

Findings:

  • The metabolic capabilities of bioartificial devices are confirmed in clinical evaluations.

Related Experiment Videos

  • Observed changes in patient serum biochemistry indicate device functionality.
  • Crucially, these devices have not yet demonstrated an improvement in patient outcomes for ALF.

    • Implications:

    • Further research is needed to translate observed metabolic functions into improved clinical outcomes for ALF patients.
    • Addressing significant safety concerns, particularly the risk of zoonotic disease transmission, is paramount for clinical adoption.
    • The potential of bioartificial devices in liver support remains high, but requires further validation and safety refinement.